New study to see how elranatamab fights tough myeloma in china
NCT ID NCT07320326
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study will observe about 159 adults in China with a hard-to-treat type of multiple myeloma that has come back or not responded to other treatments. Researchers will track how well the drug elranatamab works in everyday medical practice, looking at tumor shrinkage, survival, and quality of life. No new treatments are given—just careful monitoring of routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TCE-RRMM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.